Immuron (IMRN) Enterprise Value (2016 - 2025)
Immuron (IMRN) posted quarterly Enterprise Value of -$28305.3 for Q3 2025, up 75.72% year-over-year from -$16108.3 in Q3 2024, and up 98.44% quarter-over-quarter from -$1.8 million in Q2 2025.
Immuron (IMRN) Enterprise Value (2016 - 2025) Analysis & Trends
Immuron's Enterprise Value history runs 10 years deep, the most recent figure standing at -$28305.3 for Q3 2025.
- In Q3 2025, Enterprise Value rose 75.72% year-over-year to -$28305.3; the TTM figure through Sep 2025 stood at -$28305.3 (up 75.72% YoY), while the FY2025 annual figure was -$11.7 million, up 32.07% from the prior year.
- Enterprise Value for Q3 2025 stood at -$28305.3, up from -$1.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$28305.3 in Q3 2025, with the low at -$19.3 million in Q2 2021.
- The 5-year median for Enterprise Value is -$9.5 million (2024), against an average of -$9.3 million.
- The sharpest annual moves came in 2021 and 2023: Enterprise Value plunged 6833.34% in 2021, then soared 98.88% in 2023.
- Immuron's Enterprise Value stood at -$18.3 million in 2021, then increased by 20.77% to -$14.5 million in 2022, then increased by 14.81% to -$12.4 million in 2023, then jumped by 38.4% to -$7.6 million in 2024, then surged by 99.63% to -$28305.3 in 2025.
- Business Quant data shows IMRN's Enterprise Value at -$28305.3 in Q3 2025, -$1.8 million in Q2 2025, and -$7.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | -28,305.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | -28,305.26 |
| Jun 30, 2025 | -1.81 Mn |
| Dec 31, 2024 | -7.62 Mn |
| Sep 9, 2024 | -116,573.15 |
| Jun 30, 2024 | -7.68 Mn |
| Dec 31, 2023 | -12.38 Mn |
| Sep 28, 2023 | -11.25 Mn |
| Aug 30, 2023 | -171,597.64 |
| Jun 30, 2023 | -6.00 Mn |
| Dec 31, 2022 | -14.53 Mn |
| Aug 31, 2022 | -15.38 Mn |
| Jun 30, 2022 | -15.84 Mn |
| Dec 31, 2021 | -18.34 Mn |
| Jun 30, 2021 | -19.29 Mn |
| Dec 31, 2020 | -264,447.68 |
| Sep 1, 2020 | -3.25 Mn |
| Jun 30, 2020 | -2.13 Mn |
| Dec 31, 2019 | -5.12 Mn |
| Jun 30, 2019 | -3.59 Mn |
| Dec 31, 2018 | -4.19 Mn |